Atlas Capital Advisors Inc. Has $164,000 Position in Danaher Co. (NYSE:DHR)

Atlas Capital Advisors Inc. trimmed its holdings in Danaher Co. (NYSE:DHR) by 27.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 713 shares of the conglomerate’s stock after selling 275 shares during the quarter. Atlas Capital Advisors Inc.’s holdings in Danaher were worth $164,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the business. Kentucky Retirement Systems Insurance Trust Fund increased its stake in Danaher by 11.6% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock valued at $4,874,000 after purchasing an additional 2,202 shares in the last quarter. ORG Partners LLC increased its position in Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock valued at $636,000 after buying an additional 2,559 shares in the last quarter. Generate Investment Management Ltd acquired a new position in Danaher during the 4th quarter worth approximately $8,044,000. Compass Capital Management Inc. boosted its holdings in Danaher by 4.8% in the fourth quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock worth $54,615,000 after acquiring an additional 10,994 shares in the last quarter. Finally, Channing Global Advisors LLC grew its stake in Danaher by 42.8% in the fourth quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate’s stock valued at $1,301,000 after acquiring an additional 1,698 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Down 8.3 %

NYSE:DHR opened at $181.42 on Friday. Danaher Co. has a 12 month low of $181.20 and a 12 month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The firm’s 50 day moving average is $209.99 and its 200 day moving average is $233.99. The stock has a market capitalization of $129.66 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 2.66 and a beta of 0.86.

Danaher (NYSE:DHR) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm earned $2.09 EPS. Sell-side analysts expect that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date is Friday, March 28th. This is a positive change from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is currently 24.24%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Scotiabank began coverage on Danaher in a report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Wells Fargo & Company dropped their price objective on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Barclays decreased their target price on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. The Goldman Sachs Group raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price target on the stock in a research report on Friday, March 21st. Finally, Robert W. Baird decreased their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $278.24.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.